In the Spotlight...

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy

In a six-week, feeder-free process, human cord blood CD34+ HSCs were differentiated to NKT cells and engineered to express iNKT TCRs, anti-BCMA CARs, and IL-15, with knockout of B2M and CIITA to avoid...

Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement

Pan, Xue, and Yang et al. focused on improving efficacy of PD-1 blockade and PD-1 Ab-derived BiTEs (αPD-1). Using glycoengineering, a humanized anti-PD-1 was conjugated to a circular peptide (iRGD)2 t...

Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers

An iPSC whole call cancer vaccine combined with radiotherapy (RT) improved CT26 tumor control compared to GM-CSF-adjuvanted iPSCs or fibroblasts by enhancing tumor cell apoptosis and cytotoxic T cell ...

Principles of peptide selection by the transporter associated with antigen processing

Lee et al. performed cryo-EM experiments to analyze the structure of dimeric TAP while binding peptides. When TAP binds a peptide, the nucleotide-binding domains came closer together. The peptide N- a...

Previous Digests

Age is not just a number: age-related dysfunctional T cell subset restricts antitumor responses

June 5, 2024

Aging is known to induce immune dysfunction in cancer, but the mechanisms behind it remain poorly understood. In a recent Nature Immunology publication, Chen et al. assessed tumor-infiltrating T cells and the tumor microenvironment (TME) of young and aged...

RIGging the game: LRIG1 induces CD8+ T cell quiescence by engaging VISTA

May 29, 2024

Immune checkpoint inhibitors have revolutionized the cancer immunotherapy field, and V domain immunoglobulin suppressor of T cell activation (VISTA) has garnered attention as a potentially relevant immune regulatory molecule. In preclinical models, VISTA blockade has promoted CD8+ T cell...

A glucocorticoid game changer for B cell cancers

May 22, 2024

Glucocorticoids are used in combination with chemotherapy and rituximab for the treatment of B cell malignancies, such as diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and acute lymphoblastic leukemia (ALL). They function as glucocorticoid...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.